Phase II selection design trial of concurrent chemotherapy + cetuximab vs. chemotherapy then cetuximab in advanced non-small cell lung cancer (NSCLC).

Trial Profile

Phase II selection design trial of concurrent chemotherapy + cetuximab vs. chemotherapy then cetuximab in advanced non-small cell lung cancer (NSCLC).

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Oct 2017

At a glance

  • Drugs Carboplatin; Cetuximab; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Biomarker; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 31 Oct 2012 Actual end date Jul 2011 added as reported by ClinicalTrials.gov.
    • 10 Aug 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top